2026 ICD-10-CM Diagnosis Code T38.3X5AAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter

AHRQ’s CCSR groups this code into broader clinical categories.

• Acetohexamide

  a sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.

• Buformin

  an oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.

• Carbutamide

  a sulfonylurea antidiabetic agent with similar actions and uses to chlorpropamide. (from martindale, the extra pharmacopoeia, 30th ed, p277)

• Chlorpropamide

  a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (from martindale, the extra pharmacopoeia, 30th ed, p277)

• Gliclazide

  an oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

• Glipizide

  an oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

• Glucagon

  a 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal glucagon-like peptides. glucagon is secreted by pancreatic alpha cells and plays an important role in regulation of blood glucose concentration, ketone metabolism, and several other biochemical and physiological processes. (from gilman et al., goodman and gilman's the pharmacological basis of therapeutics, 9th ed, p1511)

• Glucagon-Like Peptide 1

  a peptide of 36 or 37 amino acids that is derived from proglucagon and mainly produced by the intestinal l cells. glp-1(1-37 or 1-36) is further n-terminally truncated resulting in glp-1(7-37) or glp-1-(7-36) which can be amidated. these glp-1 peptides are known to enhance glucose-dependent insulin release, suppress glucagon release and gastric emptying, lower blood glucose, and reduce food intake.

• Glucagon-Like Peptide 2

  a 33-amino acid peptide derived from the c-terminal of proglucagon and mainly produced by the intestinal l cells. it stimulates intestinal mucosal growth and decreased apoptosis of enterocytes. glp-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.

• Glucagon-Like Peptide Receptors

  g-protein coupled cell surface receptors that bind glucagon-like peptides and are expressed by cells in pancreatic, intestinal, and neural tissues. these receptors regulate cellular responses to blood glucose, insulin, and inflammation signals.

• Glucagon-Like Peptide-1 Receptor

  a receptor for glucagon-like peptide 1 (glp-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. glp-1 acts through glp-1r to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (gsis).

• Glucagon-Like Peptide-1 Receptor Agonists

  compounds that stimulate the activity of glucagon-like peptide-1 receptor. glucagon-like peptide-1 receptor agonists are used to treat type 2 diabetes and obesity.

• Glucagon-Like Peptide-2 Receptor

  a receptor for glucagon-like peptide 2 (glp-2) that is expressed on the surface of intestinal cells as well as neural cells. glp-2 and other peptides act through glp-2r to regulate cellular responses to blood glucose, inflammation, and food intake.

• Glucagon-Like Peptides

  peptides derived from proglucagon which is also the precursor of pancreatic glucagon. despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (glps) is the intestinal l cells. glps include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

• Glucagonoma

  an almost always malignant glucagon-secreting tumor derived from the pancreatic alpha cells. it is characterized by a distinctive migratory erythema; weight loss; stomatitis; glossitis; diabetes mellitus; hypoaminoacidemia; and normochromic normocytic anemia.

• Glucagon-Secreting Cells

  a type of pancreatic cell representing about 5-20% of the islet cells. alpha cells secrete glucagon.

• Proglucagon

  the common precursor polypeptide of pancreatic glucagon and intestinal glucagon-like peptides. proglucagon is the 158-amino acid segment of preproglucagon without the n-terminal signal sequence. proglucagon is expressed in the pancreas; intestines; and the central nervous system. posttranslational processing of proglucagon is tissue-specific yielding numerous bioactive peptides.

• Receptors, Glucagon

  cell surface receptors that bind glucagon with high affinity and trigger intracellular changes which influence the behavior of cells. activation of glucagon receptors causes a variety of effects; the best understood is the initiation of a complex enzymatic cascade in the liver which ultimately increases the availability of glucose to body organs.

• Glyburide

  an antidiabetic sulfonylurea derivative with actions like those of chlorpropamide

• Metformin

  a biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (from martindale, the extra pharmacopoeia, 30th ed, p289)

• Phenformin

  a biguanide hypoglycemic agent with actions and uses similar to those of metformin. although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (from martindale, the extra pharmacopoeia, 30th ed, p290)

• Tolazamide

  a sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

• What is a drug interaction?
• What are side effects?
• What are drug allergies?
• How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.